Navigation Links
Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
Date:7/9/2008

TORONTO, July 9 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. (TSX: LOR, AMEX: LRP) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced progress made in the Virulizin(R) development program, including the publication of two research studies on the Virulizin(R) mode of action and the issuance of a new patent for Virulizin(R) in Mexico.

"Publication of these two studies in international scientific journals adds significantly to our previous studies on Virulizin(R) anticancer mechanisms and activities," commented Dr. Aiping Young, Lorus' President and CEO. "In addition, allowance of a new patent strengthens the intellectual property position for this product, and protects the potential for expanding the use to other cancer indications in this jurisdiction."

New Virulizin(R) patent issued in Mexico

The patent, titled "Immunomodulating Compositions from Bile for the Treatment of Immune System Disorders", protects methods of treating several cancers using Virulizin(R). This is the second patent issued in Mexico for Virulizin(R), and extends patent protection for Virulizin(R) in this country to 2016. Similar patents for Virulizin(R) have also been issued in a number of other countries worldwide, including Canada, Australia, and the United States.

Virulizin(R) is currently approved for the treatment of malignant melanoma in Mexico. The new patent provides protection for the potential treatment with Virulizin(R) of additional cancers, including ovarian and lung cancers. Virulizin(R) composition, manufacturing process, and use in the treatment of cancers are also protected in Mexico under an earlier patent issued to Lorus in 2003.

Virulizin(R) has demonstrated significant anticancer activity against a wide range of human cancers in preclinical studies, and has been tested in several clinical
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
4. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
7. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... 12, 2014 This report ... used in the life science industry. Continuous ... science reagents market towards remarkable growth. The ... providers of life science reagents. , Brows ... http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . , The global life science ...
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... "International Transfection Technology Market - Global Industry Analysis, ... report to their offering. ... to introduce nucleic acids (either DNA or RNA) into ... therapy, mutation of cancer cells and protein metabolism by ...
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/10/2014)... Faso (PRWEB) July 10, 2014 ... today have access to an additional family planning ... access to contraception at all levels of the ... lower-dose formulation of a widely used contraceptive—Pfizer’s Depo-Provera® ... , Burkina Faso is the first of four ...
Breaking Biology Technology:Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6
... TurboSonic,Technologies, Inc. (OTC Bulletin Board: TSTA), a global ... control technologies, today,announced that the company,s CEO, Edward Spink ... Show., The interview gives viewers an overview of ... release., To view the clip ...
... sinus irrigation device) describes his successful treatment protocol for ... cavities using a pulsating irrigation device. This treatment has ... of sinus infections, snoring and sleep apnea., http://abclocal.go.com/kabc/story?section=news/health&id=6231390 ... ...
... Department of Labor Conference, WEST PALM BEACH, ... Department of Labor,s Recognition of Excellence Award in,the ... Deputy Assistant Secretary of Labor for Employment and,Training, ... honors,workforce investment programs from around the country that ...
Cached Biology Technology:[video] Edward Spink, CEO of TurboSonic Technologies, Inc. Discusses Contract With Biofuel Producer in Exclusive Interview on WallSt.net's 3-Minute Press Show 2Prominent Physician Achieves Success Using Topical Sinus Medications via Pulsitile Irrigation 2Workforce Alliance Receives U.S. Labor Department's Excellence Award 2Workforce Alliance Receives U.S. Labor Department's Excellence Award 3
(Date:7/11/2014)... July 11, 2014 Research and Markets ... Biometrics Technology Market - Industry Analysis Size Share Growth ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... has created a need for high level security in ... personnel authentication such as username and passwords, tokens etc. ...
(Date:7/11/2014)... Brazil- In the brains of all vertebrates, information ... an electric or chemical signal to be passed ... which are the most abundant type of synapse, ... is crucial for learning, memory, perception and cognition, ... critical for brain function. For instance, every ...
(Date:7/10/2014)... Colo. , June 27, 2014  The ... the National Institute of Standards and Technology (NIST) ... of its academic research and forensic science expert ... The Board is an element of the NIST,s ... members are among the first appointments made to ...
Breaking Biology News(10 mins):International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2Blame it on the astrocytes 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3
... Juvenile Diabetes Research Foundation, a leader in setting the ... will begin a diabetes research collaboration with Pfizer, Hadassah ... drugs to replicate and regenerate insulin-producing cells in people ... the direction of Professor Benjamin Glaser (Hadassah Medical) and ...
... Medical Center have identified a new growth factor that ... cells in culture and in laboratory animals. The discovery, ... help researchers overcome one of the most frustrating barriers ... are so few in number and so stubbornly resistant ...
... Spanish . , Feeding the amino acid tryptophan ... makes them less aggressive and easier to manage, according to ... The tryptophan-enhanced diet reduced aggression and overall behavioral activity ... is only acquired through diet, is the precursor for the ...
Cached Biology News:JDRF, Pfizer, Hadassah Medical and the Hebrew University announce collaboration 2Newly identified growth factor promotes stem cell growth, regeneration 2Tryptophan-enriched diet reduces pig aggression 2
... VSN-5 Nutating Mixer is a combination of ... a three dimensional action while providing gentle, ... quality unit can be used for a ... of specimens, tissue culture, immunoblots, staining/destaining, chromatography, ...
... The FastPlax Titer Kit is designed for determination ... of 46 days as in other methods. Classical ... appearance of plaques, but the FastPlax Kit takes ... AcNPV gp64 glycoprotein on the cell surface as ...
... Thermocycler combines top performance with exquisite design. ... speed and unparalleled temperature uniformity. The instrument ... in a spreadsheet or alternatively in a ... opens on the push of a button ...
...
Biology Products: